Inhibikase Therapeutics (IKT) Shares Outstanding (Weighted Average) (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $172.3 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $172.3 million, up 92.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $172.3 million (up 92.44% YoY), and the FY2025 annual result was $98.3 million, up 314.6% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $172.3 million in Q1 2026 per IKT's latest filing, from $98.3 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $172.3 million in Q1 2026 and troughed at $4.2 million in Q3 2022.
• A 5-year average of $38.1 million and a median of $7.5 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2023 and 2025: Shares Outstanding (Weighted Average) slumped 77.85% in 2023, then soared 1312.1% in 2025.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $4.2 million in 2022, then jumped by 42.74% to $6.0 million in 2023, then surged by 293.35% to $23.7 million in 2024, then soared by 314.6% to $98.3 million in 2025, then surged by 75.27% to $172.3 million in 2026.
• Business Quant data shows IKT's Shares Outstanding (Weighted Average) at $172.3 million in Q1 2026, $98.3 million in Q4 2025, and $90.1 million in Q3 2025.